이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
Nurix Therapeutics 관리
관리 기준 확인 4/4
현재 CEO에 대한 정보가 충분하지 않습니다.
주요 정보
Arthur Sands
최고 경영자
US$4.4m
총 보상
| CEO 급여 비율 | 13.5% |
| CEO 임기 | 10yrs |
| CEO 소유권 | 0.5% |
| 경영진 평균 재임 기간 | 4.2yrs |
| 이사회 평균 재임 기간 | 4yrs |
최근 관리 업데이트
Recent updates
Unpleasant Surprises Could Be In Store For Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) Shares
Sep 07
Nurix Therapeutics: Promising Science, Major Collaborations, Undifferentiated Data
Sep 04Nurix Therapeutics (NASDAQ:NRIX) Is In A Good Position To Deliver On Growth Plans
Jul 15Nurix Therapeutics: Protein Deg Specialist's Latest Data Establishes Bull Case
Jun 19What Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 26% Share Price Gain Is Not Telling You
May 29Nurix Therapeutics Advances Promising Protein Degraders For B-Cell Malignancies
Apr 15Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 28% Price Boost Is Out Of Tune With Revenues
Apr 14Improved Revenues Required Before Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Find Their Feet
Feb 20Nurix Therapeutics: Recovering Thanks To ASH, But I Think It's Priced Just Right For Now
Jan 16Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation
Dec 29Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 29% Dip In Price Shows Sentiment Is Matching Revenues
Oct 14Broker Revenue Forecasts For Nurix Therapeutics, Inc. (NASDAQ:NRIX) Are Surging Higher
Oct 13Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation
Sep 30Party Time: Brokers Just Made Major Increases To Their Nurix Therapeutics, Inc. (NASDAQ:NRIX) Earnings Forecasts
Apr 18We Think Nurix Therapeutics (NASDAQ:NRIX) Needs To Drive Business Growth Carefully
Apr 15We're Keeping An Eye On Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Rate
Nov 28Nurix Therapeutics GAAP EPS of -$0.90 beats by $0.07, revenue of $10.79M misses by $1.29M
Oct 06Nurix Therapeutics GAAP EPS of -$1.01 misses by $0.02, revenue of $11.43M beats by $0.93M
Jul 07FDA approves expansion of Nurix Therapeutics' phase 1 trial of NX-1607 into the U.S.
Jun 30We Think Nurix Therapeutics (NASDAQ:NRIX) Needs To Drive Business Growth Carefully
Jun 21We Think Nurix Therapeutics (NASDAQ:NRIX) Can Afford To Drive Business Growth
Mar 07Nurix: Advancing Targeted Protein Modulation Therapies
Nov 21Companies Like Nurix Therapeutics (NASDAQ:NRIX) Can Afford To Invest In Growth
Nov 21We're Not Worried About Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn
Jul 24Nurix Therapeutics appoints new operations chief
Jun 21CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| May 31 2024 | n/a | n/a | -US$165m |
| Feb 29 2024 | n/a | n/a | -US$145m |
| Nov 30 2023 | US$4m | US$591k | -US$144m |
| Aug 31 2023 | n/a | n/a | -US$149m |
| May 31 2023 | n/a | n/a | -US$157m |
| Feb 28 2023 | n/a | n/a | -US$179m |
| Nov 30 2022 | US$9m | US$572k | -US$180m |
| Aug 31 2022 | n/a | n/a | -US$171m |
| May 31 2022 | n/a | n/a | -US$154m |
| Feb 28 2022 | n/a | n/a | -US$135m |
| Nov 30 2021 | US$5m | US$539k | -US$117m |
| Aug 31 2021 | n/a | n/a | -US$99m |
| May 31 2021 | n/a | n/a | -US$89m |
| Feb 28 2021 | n/a | n/a | -US$63m |
| Nov 30 2020 | US$17m | US$521k | -US$43m |
| Aug 31 2020 | n/a | n/a | -US$37m |
| May 31 2020 | n/a | n/a | -US$21m |
| Feb 29 2020 | n/a | n/a | -US$24m |
| Nov 30 2019 | US$1m | US$474k | -US$22m |
보상 대 시장: Arthur 의 총 보상 ($USD 4.36M )은 US 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 3.43M ).
보상과 수익: Arthur 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.
CEO
Arthur Sands (62 yo)
10yrs
테뉴어
US$4,363,120
보상
Dr. Arthur T. Sands, M.D., Ph D., has been the Chief Executive Officer and Director of Nurix Therapeutics, Inc. (formerly, Nurix Inc.) since September 2014 and has been its President since June 2020. Dr. S...
리더십 팀
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| CEO, President & Director | 10yrs | US$4.36m | 0.48% $ 7.1m | |
| Chief Financial Officer | 8.5yrs | US$1.61m | 0.048% $ 714.6k | |
| Chief Scientific Officer | 4.3yrs | US$1.63m | 0.070% $ 1.0m | |
| Founder & Member of Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Founder & Member of Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Founder & Member of Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Senior Accounting Manager | no data | 데이터 없음 | 데이터 없음 | |
| Chief Technical Officer | less than a year | 데이터 없음 | 데이터 없음 | |
| Chief Legal Officer | 5yrs | US$1.65m | 0.038% $ 566.9k | |
| Chief People Officer | 2.1yrs | 데이터 없음 | 데이터 없음 | |
| Chief Business Officer | 4.2yrs | 데이터 없음 | 데이터 없음 | |
| Senior VP & Head of Early Drug Discovery | 3.7yrs | 데이터 없음 | 데이터 없음 |
4.2yrs
평균 재임 기간
58yo
평균 연령
경험이 풍부한 관리: NRIX 의 관리팀은 경험 ( 4 년 평균 재직 기간)으로 간주됩니다.
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| CEO, President & Director | 10yrs | US$4.36m | 0.48% $ 7.1m | |
| Founder & Member of Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Founder & Member of Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Founder & Member of Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Independent Chairman | 5.1yrs | US$238.29k | 0% $ 0 | |
| Member of Medical Advisory Board | 1.7yrs | 데이터 없음 | 데이터 없음 | |
| Independent Director | 2.9yrs | US$225.79k | 0% $ 0 | |
| Member of Medical Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Independent Director | 5.2yrs | US$228.29k | 0% $ 0 | |
| Independent Director | 8.4yrs | US$263.29k | 0.052% $ 768.3k | |
| Independent Director | 2.9yrs | US$225.79k | 0% $ 0 | |
| Independent Director | 2yrs | US$223.29k | 0% $ 0 |
4.0yrs
평균 재임 기간
67.5yo
평균 연령
경험이 풍부한 이사회: NRIX 의 이사회는 경험(평균 재직 기간 3.8 년)으로 간주됩니다.